CD19 and rheumatoid arthritis: Time‐ and dose‐response studies on lymphocytes from RA patients treated with RTX showed the effectiveness of the treatment through reduction of B lymphocytes (CD19+) and the inflammatory status of the lymphocyte population (Figure S5).